Simplify Logo

Full-Time

Data Reviewer

QC Specialist

Posted on 7/2/2024

BioAgilytix

BioAgilytix

501-1,000 employees

Bioanalytical testing for drug development

Biotechnology
Healthcare

Mid, Senior

Boston, MA, USA

Requires onsite presence in Boston, MA.

Category
Lab & Research
Life Sciences
Medical Research
Requirements
  • Bachelor’s degree in biological science or related field
  • 2-10 years’ experience working in biotech, pharmaceutical, CRO/CMO or similar organization
  • Knowledge and/or extensive knowledge of GxP regulations
  • Two-Four (2-4) years’ experience performing data review in a GxP environment
  • Experience with relevant bioanalytical methods such as immunoassays, cell-based assays, or qPCR
Responsibilities
  • Perform Quality Control (QC) technical, scientific, and compliance review of data and documentation
  • Identify deviations, OOS and OOT associated with Bioanalytical Operations data
  • Issue QC review observations and work closely with the scientific staff
  • Collect metrics data used to monitor the QC reviews and may identify process improvements
  • Assist in educating, guiding, and influencing the scientific staff in regard to best practices in GxP compliance

BioAgilytix provides specialized bioanalytical testing services for the pharmaceutical, biotechnology, and agricultural biotechnology industries. Their services include a variety of assays, such as pharmacokinetics (PK) and pharmacodynamics (PD) assays, which analyze how drugs behave in the body, as well as cell-based assays that test drug effects on living cells and immunogenicity assays that assess immune responses to drugs. With a laboratory in Hamburg, Germany, BioAgilytix operates globally and supports clients in developing and validating new treatments, ensuring the safety and efficacy of agricultural products, and has also contributed to COVID-19 testing efforts. Unlike many competitors, BioAgilytix focuses specifically on large molecule studies, making them a crucial partner for companies in the life sciences sector. Their goal is to facilitate the development and approval of new drugs and therapies through their comprehensive testing services.

Company Stage

Series A

Total Funding

$30.2M

Headquarters

Durham, North Carolina

Founded

2008

Growth & Insights
Headcount

6 month growth

44%

1 year growth

44%

2 year growth

44%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnerships, such as with BBI Solutions and A3P Biomedical, enhance BioAgilytix's service offerings and market reach.
  • Expansion of the Hamburg lab and the addition of new leadership positions indicate robust growth and investment in infrastructure and talent.
  • The company's role in COVID-19 testing and advanced diagnostics positions it as a critical player in addressing global health challenges.

What critics are saying

  • The cancellation of the $61.5 million expansion deal in Durham, which promised 878 jobs, could indicate potential financial or strategic setbacks.
  • High turnover in leadership, including the recent appointment of a new COO and VP of Business Development, may lead to strategic misalignments and operational disruptions.

What makes BioAgilytix unique

  • BioAgilytix specializes in large molecule studies, offering a comprehensive suite of assays that are critical for drug development, unlike competitors who may focus on small molecules.
  • Their global presence, particularly with a significant laboratory in Hamburg, Germany, allows them to support clients across multiple continents, providing a competitive edge in accessibility and reach.
  • The company's involvement in COVID-19 testing and partnerships with firms like A3P Biomedical for advanced diagnostics showcases their adaptability and commitment to addressing urgent healthcare needs.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE